<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Medium chain triglycerides: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Medium chain triglycerides: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Medium chain triglycerides: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11251" href="/d/html/11251.html" rel="external">see "Medium chain triglycerides: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="12576" href="/d/html/12576.html" rel="external">see "Medium chain triglycerides: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F191959"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Betaquik [OTC] [DSC];</li>
<li>Liquigen [OTC];</li>
<li>MCT Oil [OTC]</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52912142"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>MCT Oil</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F191967"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Nutritional Supplement</li></ul></div>
<div class="block doa drugH1Div" id="F191961"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="bb228b24-98d4-4dc7-8891-219ccb02485a">Dietary supplement/medical food</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Dietary supplement/medical food</b>:</p>
<p style="text-indent:-2em;margin-left:4em;">MCT Oil: <b>Oral:</b> 15 to 20 mL per dose (maximum daily dose: 100 mL).</p>
<p style="text-indent:-2em;margin-left:4em;">Emulsion (eg Betaquik, Liquigen): <b>Oral:</b> To be determined by the clinician or dietitian and is dependent on the age, body weight, and medical condition of the patient.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990232"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block doha drugH1Div" id="F50987546"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block doe drugH1Div" id="F191962"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F191964"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="12576" href="/d/html/12576.html" rel="external">see "Medium chain triglycerides: Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Dose to be individualized by clinician and/or dietitian based on patient age, caloric needs, tolerance, and clinical status. Initiate therapy using small amounts and gradually increasing based on patient tolerance to prevent and/or limit GI side effects (Gracey 1970; Liu 2013; Ruppin 1980).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4e399523-5ef7-43a8-b955-b39d63d47bad">Nutritional supplement</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Nutritional supplement:</b> Limited data available: Infants: MCT oil: Oral: Initial: 0.5 mL every other feeding, then advance to every feeding, then increase in increments of 0.25 to 0.5 mL/feeding at intervals of 2 to 3 days as tolerated (Gal 2007). For GI tolerability, maximum daily dose is 100 mL/<b>day</b> in divided doses (Ruppin 1980; Shah 2017).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="df85d498-37b3-4d24-95e1-d4a9ea8cb8c0">Cystic fibrosis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cystic fibrosis:</b> Limited data available: Children and Adolescents: MCT oil: Oral: Individualize dose based on patient-specific needs and tolerance; 15 mL three times daily has been reported (Gal 2007); it is recommended to initiate using small amounts and gradually increasing based on patient tolerance to prevent and/or limit GI side effects. For GI tolerability, maximum daily dose is 100 mL/<b>day</b> in divided doses (Gracey 1970; Ruppin 1980; Shah 2017).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d8440024-3bfe-4a3e-9542-d1f040df5631">Fatty acid oxidation disorders, nutritional supplementation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Fatty acid oxidation disorders, nutritional supplementation:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: <b>Note:</b> For GI tolerability, maximum daily dose is 100 mL/<b>day</b> in divided doses (Ruppin 1980; Shah 2017).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Long-chain hydroxyacyl-CoA dehydrogenase deficiency (LCHAD), Trifunctional protein (TFP) deficiency:</i> Oral: 1 to 3 g/kg/day <b>or</b> 20% to 30% of energy (Wessel 2014).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Very long-chain acyl-CoA dehydrogenase (VLCAD) deficiency:</i> Oral: 1 to 3 g/kg/day <b>or</b> 10% to 30% of energy (Wessel 2014).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a1fddc51-168b-479a-8655-2decc81110e2">Ketogenic diet</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Ketogenic diet:</b> Limited data available; optimal dose not established; consult institutional-specific protocols. For GI tolerability, maximum daily dose is 100 mL/<b>day</b> in divided doses (Ruppin 1980; Shah 2017).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Classic ketogenic diet: </i>Infants, Children, and Adolescents: Oral: Added to meals as a supplement to boost ketosis and improved lipid abnormalities; may decrease amount per meal and increase the number of meals per day to improve tolerance (Kossoff 2018). Infants usually tolerate ~10% to 25% of total calories from medium chain triglycerides (van der Louw 2016).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Medium chain triglyceride (MCT) diet:</i> Children and Adolescents: Oral: ~30% to 60% of total calories provided as MCTs; divide and administer with all meals; some patients may experience GI discomfort with the traditional MCT diet (60% of calories); to improve GI symptoms, some may utilize the modified MCT diet which provides ~30% of calories from MCTs and 30% from long chain triglycerides (Costas 2014; Kossoff 2018).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51130657"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block dohp drugH1Div" id="F51130658"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling.</p></div>
<div class="block adr drugH1Div" id="F191945"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency not defined.</p>
<p style="text-indent:-2em;margin-left:2em;">Endocrine &amp; metabolic: Decreased HDL cholesterol (&gt;6 months daily use), increased serum triglycerides (&gt;6 months daily use)</p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal: Abdominal cramps, abdominal pain, bloating, diarrhea, nausea</p></div>
<div class="block war drugH1Div" id="F23601962"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetic ketoacidosis: Avoid use in patients with uncontrolled diabetic ketoacidosis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic cirrhosis; large amounts of medium chain triglycerides (MCT) may elevate blood and spinal fluid levels of medium chain fatty acids (MCFA) due to impaired hepatic clearance of MCFA (Gracey 1970; Morgan 1974).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Patients on a low-fat diet or with fat malabsorption syndrome: Use with a source of essential fatty acids in patients on a low-fat diet or with fat malabsorption syndrome to avoid deficiency (Limketkai 2017).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: These products are medical foods and should be used under medical supervision. MCTs are not intended as a sole source of nutrition; they do not provide the recommended daily dosage of essential fatty acids. Products may contain a different caloric content. Not for parenteral use.</p></div>
<div class="block foc drugH1Div" id="F191949"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">Emulsion, Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Betaquik: (225 mL [DSC], 250 mL[DSC])</p>
<p style="text-indent:-2em;margin-left:4em;">Liquigen: (250 mL)</p>
<p style="text-indent:-2em;margin-left:2em;">Oil, Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">MCT Oil: (946 mL)</p></div>
<div class="block geq drugH1Div" id="F191939"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block adm drugH1Div" id="F191951"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;display:inline">Shake emulsions well before use. May be mixed with beverages (eg, milk) or mixed into sauces, salad dressings, or other foods. For administration of MCT Oil through a feeding tube, administer 15 mL via syringe through tube; flush with 30 mL of water after administration.</p>
<p style="text-indent:-2em;margin-left:2em;">Possible GI side effects (diarrhea, nausea, or excess gas) may be minimized if therapy is introduced gradually and ingested slowly (Gracey 1970; Ruppin 1980) or taken with food (Sharma 2014).</p></div>
<div class="block admp drugH1Div" id="F52613236"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral:</p>
<p style="text-indent:-2em;margin-left:2em;">MCT oil: Dilute prior to administration; dilute with at least an equal volume of water or other beverage (eg, coffee, tea, hot chocolate, fruit/vegetable juices [including orange or tomato], smoothies, milk, cola) (should not be cold; flavoring may be added); solution should be sipped slowly. MCT oil may also be mixed into sauces, salad dressings, or other foods such as hot cereals, soups, and broth. If adding to hot substances, ensure temperature is &lt;150°F (65.5°C) to avoid altering the flavor of the food (Shah 2017). Administer no more than 15 to 20 mL of MCT oil per dose (Greenberger 1969; Huttenlocher 1971; Ruppin 1980; Shah 2017). Initiating with meals and gradually increasing to target dose may improve tolerability (Gracey 1970; Ruppin 1980). MCT oil has been administered through feeding tubes in adult patients; feeding tube was flushed with water before and after administration (Shah 2017; manufacturer's labeling).</p>
<p style="text-indent:-2em;margin-left:2em;">Betaquik (liquid emulsion): Shake well prior to use. May be used similar to milk (ie, as a drink with or without added flavorings, added to hot tea or coffee, added to cereal, used in recipes). Best served chilled.</p>
<p style="text-indent:-2em;margin-left:2em;">Liquigen (liquid emulsion): Shake well prior to use. May be used in drinks and food. Dilution may be required for children &lt;5 years of age.</p></div>
<div class="block use drugH1Div" id="F191950"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dietary supplement:</b> An alternative source of energy used to replace or supplement long chain fats in the nutritional management of patients who cannot efficiently digest and absorb fats (Limketkai 2017).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Medical food:</b> Used to manage many metabolic and digestive abnormalities such as pancreatic insufficiency, fat malabsorption, impaired lymphocyte chylomicron transport, and severe hyperchylomicronemia; component of adult and preterm infant formulas (Łoś-Rycharska 2016).</p></div>
<div class="block dic drugH1Div" id="F191954"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">May be taken with meals; may be mixed with beverages (eg, juice, milk) or foods (eg, sauces, salad dressings). Possible gastrointestinal side effects from medication can be prevented if therapy is initiated with small supplements at meals and gradually increased according to patient's tolerance (Gracey, 1970). </p></div>
<div class="block pha drugH1Div" id="F191942"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">MCTs are saturated fatty acids in chains of 6-12 carbon atoms. They are water soluble and can pass directly through intestinal cell membranes into portal venous blood. Unlike long chain fats, MCTs do not require the presence of bile acids and pancreatic lipase for absorption. MCTs provide a source of calories while reducing the amount of malabsorbed fat remaining in stool (Gracey, 1970; Ruppin, 1980). </p></div>
<div class="block phk drugH1Div" id="F46103763"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Octanoic acid appeared in each subject by 30 minutes following ingestion; effect on seizures in children: Within 6 weeks</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: Up to 30% of dose can be absorbed unchanged as a triglyceride in the mucosal cell</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Almost entirely oxidized by the liver to acetyl CoA fragments and to carbon dioxide; little deposited in adipose tissue or elsewhere</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: As much as 20% of oral dose of MCT, recovered in expired CO2 in 50 minutes; &lt;10% elimination of medium chain fatty acids in feces</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F58193836"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Mct</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Mct</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  Betaquik (medium chain triglycerides) [prescribing information]. Alexandria, VA: Vitaflo USA LLC; received July 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Costas.2014">
<a name="Costas.2014"></a>Costas K, Tarrant S. Ketogenic diet. In: Sonneville K, Duggan C, eds. <i>Manual of Pediatric Nutrition</i>. 5th ed. People's Medical Publishing House; 2014: 445-460.</div>
</li>
<li>
<div class="reference">
                  Gal P, Reed M. Medications. In: Kliegman RM, Behrman RE, Jenson HB, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 18th ed. Philadelphia, PA: Saunders Elsevier; 2007: 2955-2999.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4918706">
<a name="4918706"></a>Gracey M, Burke V, Anderson CM. Medium chain triglycerides in paediatric patients. <i>Arch Dis Child</i>. 1970;45(242):445-452.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medium-chain-triglycerides-drug-information/abstract-text/4918706/pubmed" id="4918706" target="_blank">4918706</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4888178">
<a name="4888178"></a>Greenberger NJ, Skillman TG. Medium-chain triglycerides. <i>N Engl J Med</i>. 1969;280(19):1045-1058. doi:10.1056/NEJM196905082801906<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medium-chain-triglycerides-drug-information/abstract-text/4888178/pubmed" id="4888178" target="_blank">4888178</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Hise M, Brown JC. Lipids. In: Mueller CM, ed. <i>The ASPEN Adult Nutrition Support Core Curriculum</i>. 3rd ed. Silver Spring, MD: ASPEN; 2017:86,89.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-5166216">
<a name="5166216"></a>Huttenlocher PR, Wilbourn AJ, Signore JM. Medium-Chain Triglycerides as a Therapy for Intractable Childhood Epilepsy. <i>Neurology</i>. 1971;21(11):1097-1103.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medium-chain-triglycerides-drug-information/abstract-text/5166216/pubmed" id="5166216" target="_blank">5166216</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29881797">
<a name="29881797"></a>Kossoff EH, Zupec-Kania BA, Auvin S, et al. Optimal clinical management of children receiving dietary therapies for epilepsy: Updated recommendations of the International Ketogenic Diet Study Group. <i>Epilepsia Open</i>. 2018;3(2):175-192. doi:10.1002/epi4.12225<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medium-chain-triglycerides-drug-information/abstract-text/29881797/pubmed" id="29881797" target="_blank">29881797</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Limketkai BN, Hurt RT, Palmer LB. Short bowel syndrome. In: Mueller CM, ed. <i>The ASPEN Adult Nutrition Support Core Curriculum</i>. 3rd ed. Silver Spring, MD: ASPEN; 2017:594.</div>
</li>
<li>
<div class="reference">
                  Liquigen (medium chain triglycerides) [prescribing information]. Gaithersburg, MD: Nutricia North America; no date.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23515148">
<a name="23515148"></a>Liu YM, Wang HS. Medium-chain triglyceride ketogenic diet, an effective treatment for drug-resistant epilepsy and a comparison with other ketogenic diets. <i>Biomed J</i>. 2013;36(1):9-15. doi:10.4103/2319-4170.107154<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medium-chain-triglycerides-drug-information/abstract-text/23515148/pubmed" id="23515148" target="_blank">23515148</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28053676">
<a name="28053676"></a>Łoś-Rycharska E, Kieraszewicz Z, Czerwionka-Szaflarska M. Medium chain triglycerides (MCT) formulas in pediatric and allergological practice. <i>Prz Gastroenterol</i>. 2016;11(4):226-231. doi: 10.5114/pg.2016.61374.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medium-chain-triglycerides-drug-information/abstract-text/28053676/pubmed" id="28053676" target="_blank">28053676</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  MCT Oil (medium chain triglycerides) [prescribing information]. Highland Park, MI: Nestle Health Science; August 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4841275">
<a name="4841275"></a>Morgan MH, Bolton CH, Morris JS, Read AE. Medium chain triglycerides and hepatic encephalopathy. <i>Gut</i>. 1974;15(3):180-184.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medium-chain-triglycerides-drug-information/abstract-text/4841275/pubmed" id="4841275" target="_blank">4841275</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2021130">
<a name="2021130"></a>Pettei MJ, Daftary S, Levine JJ. Essential fatty acid deficiency associated with the use of a medium-chain-triglyceride infant formula in pediatric hepatobiliary disease. <i>Am J Clin Nutr</i>. 1991;53(5):1217-1221. doi:10.1093/ajcn/53.5.1217<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medium-chain-triglycerides-drug-information/abstract-text/2021130/pubmed" id="2021130" target="_blank">2021130</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7428670">
<a name="7428670"></a>Ruppin DC, Middleton WRJ. Clinical use of medium chain triglycerides. <i>Drugs</i>. 1980;20(3): 216-224.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medium-chain-triglycerides-drug-information/abstract-text/7428670/pubmed" id="7428670" target="_blank">7428670</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Shah ND, Limketkai BN. The use of medium-chain triglycerides in gastrointestinal disorders. <i>Pract Gastroenterol</i>. 2017;41(2):20-28.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24413538">
<a name="24413538"></a>Sharma A, Bemis M, Desilets AR. Role of medium chain triglycerides (Axona) in the treatment of mild to moderate Alzheimer's disease. <i>Am J Alzheimers Dis Other Demen</i>. 2014;29(5):409-414. doi: 10.1177/1533317513518650.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medium-chain-triglycerides-drug-information/abstract-text/24413538/pubmed" id="24413538" target="_blank">24413538</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27470655">
<a name="27470655"></a>van der Louw E, van den Hurk D, Neal E, et al. Ketogenic diet guidelines for infants with refractory epilepsy. <i>Eur J Paediatr Neurol</i>. 2016;20(6):798-809. doi:10.1016/j.ejpn.2016.07.009<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/medium-chain-triglycerides-drug-information/abstract-text/27470655/pubmed" id="27470655" target="_blank">27470655</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wessel.2014">
<a name="Wessel.2014"></a>Wessel A, Rohr F. Inborn errors of metabolism. In: Sonneville K, Duggan C, eds. <i>Manual of Pediatric Nutrition</i>. 5th ed. People's Medical Publishing House; 2014: 461-483.</div>
</li></ol></div><div id="topicVersionRevision">Topic 10132 Version 87.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
